Clinical Trials /

Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

NCT04098068

Description:

This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in patients with MSI (Microsatellite Unstable) negative cancer with a mutator phenotype.

Related Conditions:
  • Malignant Solid Tumor
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)
  • Official Title: Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors

Clinical Trial IDs

  • ORG STUDY ID: J1365 (Cohort D)
  • SECONDARY ID: MK-3475-016
  • SECONDARY ID: NA_00085756
  • NCT ID: NCT04098068

Conditions

  • High Tumor Mutation Burden
  • High TMB
  • MSS (Microsatellite Unstable)

Interventions

DrugSynonymsArms
MK-3475MSI Negative with Mutator Phenotype

Purpose

This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in patients with MSI negative cancer with a mutator phenotype.

Trial Arms

NameTypeDescriptionInterventions
MSI Negative with Mutator PhenotypeExperimental
  • MK-3475

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with hypermutated MSI negative cancer

          -  Have measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

          -  Adequate organ function as defined by study-specified laboratory tests

          -  Must use acceptable form of birth control through the study and for 28 days after
             final dose of study drug

          -  Signed informed consent form

          -  Willing and able to comply with study procedures

          -  Agree to have a biopsy of their cancer

          -  Patients with colon cancer must have received at least two prior cancer therapy
             regimens.

          -  Patients with other cancer types must have received at least one prior cancer therapy

          -  Progressive disease

        Exclusion Criteria:

          -  Patients with uncontrolled intercurrent illness, including but not limited to ongoing
             or active infection, systematic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia or psychiatric condition that would limit compliance with study
             requirements.

          -  Patients who have had chemotherapy or biological cancer therapy within 2 weeks prior
             to the first dose of study drug

          -  Patients who have had radiation within 2 weeks prior to the first dose of study drug

          -  Patients who have undergone major surgery within 4 weeks of dosing of investigational
             agent

          -  Patients who have received another investigational product or investigational device
             within 4 weeks prior to receiving study drug

          -  Patients who have received any of the following concomitant therapy: Interleukin-2
             (IL-2), interferon, or other non-study immunotherapy regimens, immunosuppressive
             agents, other investigational therapies or chronic use of systemic corticosteroids
             within one week prior to first dose of study drug

          -  Patients who have received a live vaccine within 4 weeks prior to or after any dose of
             MK-3475 (exception: inactivated flu vaccines)

          -  Patients who have received growth factors, including but not limited to
             granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony
             stimulating factor (GM-CSF), erythropoietin, etc. within 2 weeks of study drug
             administration

          -  Patient who have had prior treatment with anti-PD-1 (anti-programmed cell death
             protein 1), anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, or anti-CTLA-4
             antibodies

          -  Patients with history of any autoimmune disease:inflammatory bowel disease, (including
             ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive
             sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis,
             central nervous system (CNS) or motor neuropathy considered to be of autoimmune
             origin.

          -  Patients who have known history of infection with HIV, hepatitis B, or hepatitis C

          -  Patients with evidence of interstitial lung disease

          -  Systemically active steroid use

          -  Patients on home oxygen

          -  Patients with oxygen saturation of <92% on room air by pulse oximetry

          -  Pregnant or lactating

          -  Conditions, including alcohol or drug dependence, or intercurrent illness that would
             affect the patient's ability to comply with study visits and procedures

          -  Patient with known active central nervous system metastases and/or carcinomatous
             meningitis.

          -  Patients with primary brain tumors.

          -  Requires any other form of systemic or localized antineoplastic therapy while on study

          -  Has any tissue or organ allograft

          -  Patients with history of allogeneic hematopoeitic stem cell transplant
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Objective Response Rate in Patients with MSI-negative Solid Tumor Malignancies with a Mutator Phenotype
Time Frame:4 years
Safety Issue:
Description:

Secondary Outcome Measures

Measure:Overall survival
Time Frame:4 years
Safety Issue:
Description:
Measure:PFS in Patients at 28 Weeks Using RECIST 1.1
Time Frame:4 years
Safety Issue:
Description:
Measure:Overall Response Rate
Time Frame:4 years
Safety Issue:
Description:
Measure:Disease Control Rate
Time Frame:4 years
Safety Issue:
Description:
Measure:Number of Participants Experiencing Immune-related Toxicities (IRAEs)
Time Frame:4 years
Safety Issue:
Description:

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Trial Keywords

  • BRAF pv600E
  • TGFBR2
  • Mutation load
  • Tumor mutation load
  • Mutation burden
  • Tumor mutation burden (TMB)
  • Hypermutation
  • POLE
  • MSI Negative with Mutator Phenotype (High Tumor Mutation Burden)
  • TMB

Last Updated